Promoting the social implementation of digital and mobile health: effects of regulation on user and non-user behavior in East Asia.

This study conducted policy and regulation analyses and user acceptance surveys in three East Asian countries with developed telecommunication infrastructure (China, South Korea, and Japan) to determine the most effective way to implement mobile health (mHealth). Regional differences in users' emphasis on the purpose of mHealth, including medical information referral or health management, appear to be influenced by regional regulation, thus making regulation analysis important when considering mHealth penetration strategies. Potential mHealth users have high expectations for medical information and correspondence, which is crucial for the pharmaceutical industry in terms of providing information and retaining patients.

Recent trends in interorganizational deal networks in pharmaceutical and biotechnology industries.

While there have been trends in drug discovery from small molecules to new chemical modalities since the large mergers and acquisitions (M&A) of pharmaceutical companies in the late 2000s, trends in interorganizational deal networks have not been well addressed. We investigated the changing trends in interorganizational deals in the pharmaceutical and biotechnology industries. The results demonstrated that there have been changing trends, including a growing number of spinouts from academia and M&A in the United States and Europe.

What is the importance of difference in LCM strategy in drug development? - Learnings from Keytruda and Opdivo.

Immune checkpoint inhibitors have changed how cancer is treated. As of February 2022, six immune checkpoint inhibitors had been approved, with Keytruda and Opdivo accounting for the majority of global sales. Here, the impact of the differences in commercial success between Keytruda and Opdivo is reviewed by analyzing inter-organizational deals since their launch in 2014.

Superiority of Mild Interventions against COVID-19 on Public Health and Economic Measures.

(1) Background: During the global spread of COVID-19, Japan has been among the top countries to maintain a relatively low number of infections, despite implementing limited institutional interventions and its high population density. This study investigated how limited intervention policies have affected public health and economic conditions in the COVID-19 context and aimed to gain insight into the effective and sustainable measures against new infectious diseases in densely inhabited areas. (2) Methods: A system dynamics approach was employed.

Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents.

We studied the overview of drug discovery and development to understand the recent trends and potential success factors of interorganizational collaboration by reviewing 1204 transactions performed until 2019 for 107 anticancer drugs approved by the US Food and Drug Administration (FDA) from 1999 to 2018. Immune checkpoint blockade was found to be a significantly active area in interorganizational transactions, especially the number of alliances, compared with other mechanisms of action of small molecules and biologics for cancer treatment. Furthermore, the analysis of pembrolizumab and nivolumab showed that the number of approved indications for these two drugs has been rapidly expanding since their first approval in 2014.

Effectiveness of Social Measures against COVID-19 Outbreaks in Selected Japanese Regions Analyzed by System Dynamic Modeling.

In Japan's response to the coronavirus disease 2019 (COVID-19), virus testing was limited to symptomatic patients due to limited capacity, resulting in uncertainty regarding the spread of infection and the appropriateness of countermeasures. System dynamic modelling, comprised of stock flow and infection modelling, was used to describe regional population dynamics and estimate assumed region-specific transmission rates. The estimated regional transmission rates were then mapped against actual patient data throughout the course of the interventions.